SFCA3006: Significantly Greater Improvements in Post-Dose FEV1 Seen with FSC500/50 vs. FP500

Endpoint

(4%)

(13%)

(22%)

(24%)

*Pɘ.001 vs FP

*

? FEV1 (ml)

Previous slide

Next slide

Back to first slide

View graphic version